Patent classifications
A61K47/6949
Plant medium including an oxygen-enabled composition
A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 μm or less, and which may be homogeneous.
ANTIMICROBIAL NANO-SURFACTANT AND METHODS
An antimicrobial composition of buckminsterfullerene with saponified phosphorus acid functional groups is provided to disassemble or make virus particles inert, and to inhibit viral and fungal proteases using catalytic desulfurization. This composition is formulated to prevent or to treat novel corona viruses including emerging strains of SARS-Cov-2, as well as fungal pathologies such as valley fever and respiratory ailments such as chronic obstructive pulmonary disorder (COPD) and pneumonia. Virus particles are implicated in the development of cancers. The antiviral properties further enable the composition to prevent conditions leading to uncontrolled cellular proliferation, neoplasms, degenerative malignancy, and to help treat chronic inflammatory diseases associated with or leading to induce cancer in virus infected cells. The composition can be produced at low temperatures through reactive shear mixing. Delivery methods include ingestion, topical application, inhalation, or injection when used as a medicament or as a food supplement.
TUBULAR SUPRAMOLECULAR POLYMERS
The present invention provides the design of a class of prodrugs for self-assembly into therapeutic tubular supramolecular polymers and their use in a wide variety of applications. The therapeutic tubular supramolecular polymers can be used to formulate drugs and imaging agents for in vitro and in vivo uses.
STARCH-DERIVED CLATHRATE-FORMING COMPOSITIONS
Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by α-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.
STARCH-DERIVED CLATHRATE-FORMING COMPOSITIONS
Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by α-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.
FULLERENE GABA DOPA AND METHODS
A novel dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations into neural cell membranes and to disassemble salt-bridge stabilized toxic protein plaques. These properties function to mitigate cognitive deficits in neurological diseases such as Parkinson's disease and Alzheimer's disease, as well as to reduce the severity of Inflammatory Bowel Syndrome, and aging related reactive oxygen species damage by promoting the sequestration and termination of free radicals and reactive oxygen species. The composition comprises C60 bonded to one or more gamma amino butyric acid molecules and one or more molecules of either levodopa or dopamine. The composition can be produced at low temperatures through reactive shear milling. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity on aging to promote mental performance and health-span improvement.
C60 GLUTATHIONE DOPA AND METHODS
A novel dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations into neural cell membranes and to disassemble salt-bridge stabilized toxic protein plaques. These properties function to mitigate cognitive deficits in neurological diseases such as Parkinson's disease and Alzheimer's disease, as well as to reduce the severity of aging related reactive oxygen species damage by the sequestration and termination of free radicals and reactive oxygen species. The composition comprises C60 bonded to one or more glutathione molecules and one or more molecules of either levodopa or dopamine. The composition can be produced at low temperatures through reactive shear milling. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity on aging to promote mental performance and health-span improvement.
Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
- Anna Rita Blanco ,
- Maria Luisa Bondi' ,
- Gennara Cavallaro ,
- Grazia Maria Letizia Consoli ,
- Emanuela Fabiola Craparo ,
- Gaetano Giammona ,
- Mariano Licciardi ,
- Giovanna Pitarresi ,
- Giuseppe Granata ,
- Patrizia Saladino ,
- Clara La Marco ,
- Irene Ceidda ,
- Salvatore Papasergi ,
- Patrizia Guarneri ,
- Salvatore Cuzzocrea ,
- Emanuela Esposito ,
- Santa VIOLA
Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
- Anna Rita Blanco ,
- Maria Luisa Bondi′ ,
- Gennara Cavallaro ,
- Grazia Maria Letizia Consoli ,
- Emanuela Fabiola Craparo ,
- Gaetano Giammona ,
- Mariano Licciardi ,
- Giovanna Pitarresi ,
- Guiseppe Granata ,
- Patrizia Saladino ,
- Clara La Marca ,
- Irene Deidda ,
- Salvatore Papasergi ,
- Patrizia Guarneri ,
- Salvatore Cuzzocrea ,
- Emanuela Esposito ,
- Santa Viola
Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
Glyco-Metal-Organic Frameworks-based Hepatic Targeted Therapeutic Drug and Preparation Method Thereof
The disclosure discloses a glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and a preparation method thereof, and belongs to the field of biomedicine. The disclosure loads a chemotherapeutic drug onto specific metal-organic frameworks, and modifies targeted molecule galactose on the surface of the materials through amide reaction. The biocompatibility and cytotoxicity of the obtained hepatic targeted therapeutic drug have been carefully evaluated at the cellular level. The hepatic targeted therapeutic drug of the disclosure has good stability and acidic pH triggered drug release property, and can exert the synergistic therapeutic effect of photodynamic therapy and chemotherapy. In addition, in vivo behavioral tracing and therapeutic efficacy are evaluated in mouse models with subcutaneous solid tumor and tumor in situ, and the disclosure is expected to play a huge role in clinical applications.